The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

This designation highlights the potential of amlenetug as a treatment option for people living with Multiple System Atrophy. We are hopeful of the potential for amlenetug to slow the clinical ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...

UK-based public health agency, Knowledge?Action?Change (K?A?C), is launching a free online course called Understanding ...

If you want to read more about the recent tariffs imposed by the US you can look at the 10 Most Undervalued High Quality ...

UK retail banking operations are facing a growing mental health challenge among frontline staff, driven by evolving role demands, rising customer aggression, and the complexities of hybrid work, ...